Kantonsspital St.Gallen
login

Corrigendum to "Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany"

Andreas Schneeweiss, Johannes Ettl, Diana Lüftner, Matthias W Beckmann, Erik Belleville, Peter A Fasching, Tanja N Fehm, Matthias Geberth, Lothar Häberle, Peyman Hadji, Andreas D Hartkopf, Carsten Hielscher, Jens Huober, Eugen Ruckhäberle, Wolfgang Janni, Hans Christian Kolberg, Christian M Kurbacher, Evelyn Klein, Michael P Lux, Volkmar Müller, Naiba Nabieva, Friedrich Overkamp, Hans Tesch, Elena Laakmann, Florin-Andrei Taran, Julia Seitz, Christoph Thomssen, Michael Untch, Pauline Wimberger, Rachel Wuerstlein, Bernhard Volz, Diethelm Wallwiener, Markus Wallwiener & Sara Y Brucker

citation Schneeweiss A, Ettl J, Lüftner D, Beckmann M W, Belleville E, Fasching P A, Fehm T N, Geberth M, Häberle L, Hadji P, Hartkopf A D, Hielscher C, Huober J, Ruckhäberle E, Janni W, Kolberg H C, Kurbacher C M, Klein E, Lux M P, Müller V, Nabieva N, Overkamp F, Tesch H, Laakmann E, Taran F A, Seitz J, Thomssen C, Untch M, Wimberger P, Wuerstlein R, Volz B, Wallwiener D, Wallwiener M, Brucker S Y. Corrigendum to "Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany". Breast 2021; 55:138-139.
   
type journal paper/review (English)
date of publishing 05-01-2021
journal title Breast (55)
ISSN electronic 1532-3080
pages 138-139
PubMed 33413981
DOI 10.1016/j.breast.2020.12.007